Bioprocessing & Pharma
The Oral GLP-1 Tracker: Novo's Wegovy pill back on track as Lilly's momentum slows
By Angus Liu , Kevin Dunleavy , Fraiser Kansteiner · 8/21/2026
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
This is a preview. Read the complete article on Fierce Pharma.
Read the full article →